Chemistry:SCYX-7158
From HandWiki
Short description: Antiprotozoal drug to treat sleeping sickness
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H14BF4NO3 |
| Molar mass | 367.102 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Acoziborole (SCYX-7158) is an antiprotozoal drug invented by Anacor Pharmaceuticals in 2009,[1] and now under development by the Drugs for Neglected Diseases Initiative for the treatment of African trypanosomiasis (Sleeping sickness). It is a structurally novel drug described as a benzoxaborole derivative, and is a one-day, one-dose oral treatment. Phase I human clinical trials were completed successfully in 2015, and it is now in Phase IIb/III trials being carried out in the Democratic Republic of the Congo, where most cases of sleeping sickness occur.[2]
See also
References
- ↑ "SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis". PLOS Neglected Tropical Diseases 5 (6): e1151. June 2011. doi:10.1371/journal.pntd.0001151. PMID 21738803.
- ↑ "DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness". 9 September 2015. http://www.news-medical.net/news/20150909/DNDi-announces-successful-completion-of-SCYX-7158-Phase-I-study-for-treatment-of-sleeping-sickness.aspx.
 |
